Roth Capital Confident in Amarin (AMRN) Vascepa Approval After FDA AdCom Deep Dive
Tweet Send to a Friend
In a note to clients this morning, Roth Capital analyst Yasmeen Rahimi weighed in on Amarin Corporation (NASDAQ: AMRN) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


